Rodríguez-Santos O, Celio-Murillo R, Laurrabaquio-Miranda AM

Language: Spanish
References: 20
Page: 124-132
PDF size: 163.70 Kb.

ABSTRACT

The records of patients from the Allergology Service in the Previsora Policlinic, Camagüey were revised to evaluate benefits and risks of the subcutaneous immunotherapy (ITSC) with extracts of acari. The study was observational, analytic and retrospective of cases and controls in allergic rhinoconjunctivitis and bronchial asthma. A total of 160 subjects, older than 18 years old, were chosen. Eighty out of them had already received ITSC with dose increase during 13 weeks and maintenance with monthly injections during 18 months. A total of 80 patients who only received prevention measures and medications during the crises were paired. Questionnaires were applied for quality of rhinoconjunctivitis life and asthma, about the consumption of medications and the frequency of the crises. The adverse events were measured, as they were local and systemic to the cutaneous tests, to the ITSC and the different pharmacological treatments. There was a significant increase of the punctuation of life quality questionnaires, (p=0.011). The consumption of medications decreased in both the cases and the controls, without significant differences (p=0.083). The frequency of the rhinitis and asthma crises decrease in the group of ITSC (p=0.029). Slight local and systemic reactions were reported in both groups with Odds ratio (OR)=2.029 in the ITSC group, with a 95% confidence interval of 1.114–3.967 (p=0.019). The results show that the subcutaneous immunotherapy with acari offers benefits and few risks to patients with allergic rhinoconjunctivitis and asthma.

REFERENCES

1. Dalkan C, Galip N, Tekguc H, Cobanoglu N, Bahceciler N. High prevalence of allergy in North Cypriot children. Paediatr Int Child Health 2014;34(1):37-42.

2. Petersen KD, Kronborg C, Larsen JN, Dahl R, Gyrd-Hansen D. Patient related outcomes in a real life prospective follow up study: Allergen immunotherapy increase quality of life and reduce sick days. World Allergy Organ J 2013;6(1):15. Disponible: doi: 10.1186/1939-4551-6-15

3. Calderon MA, Casale TB, Nelson HS, Demoly P. An evidencebased analysis of house dust mite allergen immunotherapy: A call for more rigorous clinical studies. J Allergy Clin Immunol 2013;132(6):1322-36.

4. Rodríguez O, Labrada A, Célio R, Aboukhair F, Meli VR, Barata HJ, et al. Comparación de la potencia de extractos alergénicos de ácaros en pacientes con asma y rinitis alérgica. VacciMonitor 2012;21(1):25-9.

5. Hyland ME. The influence of beliefs on the quality of life of patients with allergic diseases. Clin Exp Allergy 1999;29:1591- 2.

6. Yepes-Núñez JJ, Gómez C, Espinoza Y, Cardona R. The impact of subcutaneous immunotherapy with Dermatophagoides farinae and Dermatophagoides pteronyssinus on the quality of life of patients with allergic rhinitis and asthma. Biomédica 2014;34(2):282-90.

7. Juniper E, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clinical Experimental Allergy 1991;21:77- 83.

8. Juniper E. Cuestionario sobre calidad de vida para pacientes con Asma: versión con lista uniforme de actividades (AQLQ(S)) [en línea]. [Oslo]: QOL Technologies Ltd;2001. Disponible en: http://www.qoltech.co.uk

9. DIATER Depot. Guía Farmacoterapéutica de Inmunoterapia [en línea]. [Madrid]: Comité de Inmunoterapia de la Sociedad Española de Alergología e Inmunología Clínica (SEAIC); 2014. Disponible en: http://www.vacunasalergia.es/frontend/ isea/base.php

10. Rodríguez SO. Inmunoterapia sublingual en rinitis alérgica y asma en niños de dos a cinco años sensibilizados con ácaros. Rev Alerg Mex 2008;55(2):71-5.

11. Reinhold T, Ostermann J, Thum-Oltmer S, Brüggenjürgen B. Influence of subcutaneous specific immunotherapy on drug costs in children suffering from allergic asthma. Clin Transl Allergy 2013;3(1):30. Disponible en: doi: 10.1186/2045-7022-3-30

12. Lai X, Li J, Xiao X, Liu E, Zhang C, Wang H, et al. Specific IgG4 production during house dust mite immunotherapy among age, gender and allergic disease populations. Arch Allergy Immunol 2013;160(1):37-46.

13. Eifan AO, Calderon MA, Durham SR. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther 2013;13(11):1543-56.

14. Liu J, Zhang XB, Feng HY, Huang JF, Zhang MZ, Wang LB. Impact factors for efficacy of specific immunotherapy in children with dust mite allergic asthma. Zhongguo Dang Dai Er Ke Za Zhi 2013;15(10):854-9.

15. Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Two year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing subcutaneous and sublingual immunotherapy. Asian Pac J Allergy Immunol 2013;31(3):233-41.

16. Kim JM, Lin SY, Suarez-Cuervo C, Chelladurai Y, Ramanathan M, Segal JB, et al. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review. Pediatrics 2013;131(6):1155-67.

17. Passalacqua G. Specific immunotherapy in asthma: a comprehensive review. J Asthma 2014;51(1):29-33.

18. MINSAP. Alergeno contra Dermatophagoides siboney (valergen Ds), alergeno contra Dermatophagoides pteronyssinus (valergen Dp), alergeno contra Blomia tropicalis (valergen Bt). En: Formulario nacional de medicamentos [en línea]. La Habana: MINSAP;2014. Disponible en: http://fnmedicamentos.sld.cu/index.php? P=Home

19. Rieker-Schwienbacher J, Nell MJ, Diamant Z, van R, Distler A, Boot JD, et al. Open-label parallel dose tolerability study of three subcutaneous immunotherapy regimens in house dust mite allergic patients. Clin Transl Allergy 2013;3(1):16. Disponible en: doi: 10.1186/2045-7022-3-16

20. Cox L, Calderón M, Pfaar O. Subcutaneous allergen immunotherapy for allergic disease: examining efficacy, safety and cost-effectiveness of current and novel formulations. Immunotherapy 2012;4(6):601-16.